KYMERA THERAPEUTICS INC. - COMMON STOCK

Kymera Therapeutics to Participate in Upcoming September Conferences

29 Aug 2022 07:30:00 By Nasdaq GlobeNewswire

Kymera Announces $150 Million Private Placement Equity Financing

19 Aug 2022 07:30:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Second Quarter 2022 Financial Results and Provides a Business Update

09 Aug 2022 07:00:01 By Nasdaq GlobeNewswire

Kymera Therapeutics to Report Second Quarter 2022 Results on August 9

27 Jul 2022 07:30:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Strengthens Board of Directors with Appointment of People and Business Leader Leigh Morgan

08 Jul 2022 07:30:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Peripheral T-Cell Lymphoma

01 Jun 2022 08:42:40 By Nasdaq GlobeNewswire

Kymera Therapeutics to Present Pre-clinical Data at the EULAR 2022 Congress Showing STAT3 Degradation Blocked Th17 Development and Prevented Rheumatoid Arthritis

01 Jun 2022 07:00:01 By Nasdaq GlobeNewswire

Kymera Therapeutics Presented Preclinical Data Showcasing Impact of IRAK4 Degrader KT-474 on Immune and Skin Cells at the Society for Investigative Dermatology Annual Meeting

20 May 2022 07:30:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Share Novel Preclinical Findings Reinforcing the Advantage of IRAK4 Degraders over Kinase Inhibitors as well as First STAT3 Degrader Results in a Preclinical Model of Th17 Inflammation

05 May 2022 08:00:02 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces First Quarter 2022 Financial Results and Provides a Business Update

03 May 2022 07:00:01 By Nasdaq GlobeNewswire

Kymera Therapeutics to Report First Quarter 2022 Results and Announces Participation at Upcoming Investor Conferences

19 Apr 2022 08:00:02 By Nasdaq GlobeNewswire

Kymera Therapeutics Presents Preclinical Data Highlighting Biological Superiority of MDM2 Degradation over Inhibition and Shares Profile of Clinical Candidate KT-253 at the American Association for Cancer Research (AACR) Annual Meeting 2022

08 Apr 2022 13:02:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Participate in Upcoming March Investor Conferences

02 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides a Business Update

24 Feb 2022 07:00:03 By Nasdaq GlobeNewswire

Kymera Therapeutics to Participate in Upcoming January and February Investor Conferences

25 Jan 2022 08:00:01 By Nasdaq GlobeNewswire

Kymera Therapeutics Appoints Healthcare Industry Leader John Maraganore, Ph.D., to Board of Directors

18 Jan 2022 08:00:05 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Key 2022 Goals and Milestones to Support Its Evolution into a Fully Integrated Degrader Medicines Company

10 Jan 2022 07:00:02 By Nasdaq GlobeNewswire

Kymera Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022

04 Jan 2022 08:00:02 By Nasdaq GlobeNewswire

Kymera Discloses New KT-474 Clinical Data, Unveils New Development Program, Provides Oncology Pipeline as well as Platform and Discovery Updates, and Outlines 5-year Vision and Goals at 2021 R&D Day

16 Dec 2021 07:00:01 By Nasdaq GlobeNewswire

Kymera Therapeutics Presents Positive Preclinical Data on Selective STAT3 Degraders for Hematological and Solid Tumor Malignancies at 63rd American Society of Hematology (ASH) Annual Meeting

13 Dec 2021 08:00:01 By Nasdaq GlobeNewswire